UNIGE document Scientific Article - Review
previous document  unige:78592  next document
add to browser collection

Vascularites systémiques : nouvelles nomenclature et approches thérapeutiques

Published in Revue médicale suisse. 2014, vol. 10, no. 426, p. 854-858
Abstract A novel nomenclature of systemic vasculitides is proposed by the 2012 Chapel Hill Consensus Conference. It aims at substituting established eponyms and introducing new terms and groups closer to our current understanding of vasculitis pathophysiology. In parallel, a therapeutic revolution is taking place partially based on the concept of re-induction of immune tolerance for ANCA-associated vasculitis (AAV). Two major multicentric randomized studies have shown that rituximab (RTX), monoclonal antibody capable of selectively killing B lymphocytes, is not inferior when compared to cyclophosphamide (CYC) to induce remission in AAV, and superior in the case of disease relapse. Thus, a hot debate is taking place whether or not to maintain CYC or use RTX in AAV. An individual-based choice may be wise for the moment being.
Keywords Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy/immunology/physiopathologyAntibodies, Monoclonal, Murine-Derived/therapeutic useB-Lymphocytes/immunologyCyclophosphamide/therapeutic useHumansImmune ToleranceImmunologic Factors/therapeutic useImmunosuppressive Agents/therapeutic useSystemic Vasculitis/drug therapy/immunology/physiopathologyTerminology as Topic
PMID: 24834643
Full text
Article (Published version) (1.2 MB) - document accessible for UNIGE members only Limited access to UNIGE
Research group La matrice extracellulaire (651)
(ISO format)
ALLALI, Danièle, CHIZZOLINI, Carlo. Vascularites systémiques : nouvelles nomenclature et approches thérapeutiques. In: Revue médicale suisse, 2014, vol. 10, n° 426, p. 854-858. https://archive-ouverte.unige.ch/unige:78592

313 hits

0 download


Deposited on : 2015-12-14

Export document
Format :
Citation style :